A future strategy for the treatment of patients with ulcerative colitis
Thursday, June 24, 2010 - 16:30
in Health & Medicine
A research team from China focused on the effects of the chemokine stromal cell-derived factor-1 receptor (CXCR4) antagonist AMD3100 on the intestinal epithelial barrier. They found that CXCR4 antagonist AMD3100 exerts therapeutic effects on experimental colitis by inhibiting colonic inflammation and enhancing epithelial barrier integrity.